TL;DR
- The clock on an FDA Warning Letter response usually runs 15 working days from the letter's date, a norm set by FDA's Regulatory Procedures Manual rather than a fixed statute (FDA Regulatory Procedures Manual, Chapter 4).
- The first 24 hours should focus on internal notification, document preservation, and confirming exactly what was cited — not drafting a response yet.
- Rushing a written response in the first day is a common mistake; FDA's own adequacy factors reward a complete, verified corrective action plan over speed alone.
- A firm that suspends the affected operation while it investigates is making a defensible choice FDA has favorably referenced in other enforcement contexts, though it isn't a formal requirement.
What to Do in the First 24 Hours After an FDA Warning Letter Arrives
A Warning Letter lands, and the instinct on a compliance team is to start drafting a response immediately. That instinct is understandable and slightly wrong. The first 24 hours matter more for what they set up than for what they produce — a clean, verified foundation the actual response will be built on over the following days.
Step 1: Get the Letter to the Right People, Fast
The first move is internal, not external: get the full letter, not a summary, in front of the people who actually run the cited operation — quality, manufacturing or clinical leadership, regulatory affairs, and legal. A Warning Letter response ultimately has to speak to specific technical citations, often referencing 21 CFR sections and specific observed instances, and someone summarizing secondhand risks losing exactly the detail that matters.
Step 2: Read the Letter Line by Line Against the Underlying Form 483
If the Warning Letter followed an inspection, pull the original Form 483 (if one was issued) and compare it side by side with the Warning Letter's citations. FDA's Warning Letter usually reflects headquarters review of the district's inspectional findings, and it can narrow, sharpen, or occasionally expand on what the Form 483 originally flagged. Understanding exactly what carried forward, and how it's now phrased, prevents a response from answering the wrong version of the concern.
Step 3: Issue a Document and Data Preservation Notice
Before anyone starts drafting corrective actions, put a formal hold on any records, batch data, complaint files, or communications related to the cited systems. This isn't just good practice — a Warning Letter response that later turns out to rely on incomplete or altered records is a documentation-integrity problem layered on top of the original citation. A simple internal memo naming the specific record types and systems under hold, sent same-day, is enough to start.
Step 4: Decide Whether to Pause the Affected Operation
This is a judgment call, not a formal FDA requirement, but it's worth making deliberately rather than by default. If the citation involves an active safety risk — a contamination pathway, a validated process running out of control, a labeling error still shipping — many firms choose to pause that specific operation while they investigate, even before FDA asks. FDA's own enforcement history includes cases where a firm's voluntary suspension was referenced as a mitigating factor in how the agency characterized the firm's response. A blanket shutdown of unrelated operations, on the other hand, is rarely necessary and can create its own supply and quality risks.
Step 5: Identify Who Owns the Response, and Set an Internal Deadline Earlier Than FDA's
FDA's Regulatory Procedures Manual, Chapter 4, generally expects a written response within 15 working days of the Warning Letter's date, though the exact adequacy standard is about substance, not just timing (FDA RPM, Chapter 4). Set an internal deadline several days ahead of that external one — a response drafted with no buffer for internal legal and quality review is more likely to contain the kind of gaps FDA has repeatedly flagged as inadequate in real cases, like a stated CAPA plan without the documentation to support it.
Step 6: Start the Root-Cause Investigation, Not the Corrective Action Plan
In the first 24 hours, the priority is starting a documented investigation into why the citation happened, not committing to a specific fix. FDA's evaluation factors weigh whether a corrective action addresses the underlying system, not just the specific instance cited — jumping straight to "we'll retrain staff" without first establishing why the failure occurred is a common way responses fall short later.
Step 7: Loop In Anyone Who Needs to Know Outside the Company
Depending on the citation, this can include a notified body, an accreditation body, a key customer under a quality agreement, or — for a public company — investor relations and disclosure counsel. A Warning Letter is a public document FDA posts, and stakeholders often find out independently; getting ahead of that with accurate internal framing is better than a scramble after the fact.
What Not to Do in the First 24 Hours
- Don't send a rushed, incomplete response to "buy goodwill" — FDA's adequacy review looks at substance, not speed alone.
- Don't let the team that was cited investigate itself with no oversight — a documented, credible investigation typically involves quality or an independent function, not just the operators directly involved.
- Don't destroy or "clean up" records related to the citation — this converts a citation into a potential data-integrity problem.
- Don't assume a Warning Letter is final — it's an FDA position at a point in time, and the formal 15-working-day response window exists specifically because FDA expects substantive engagement, not silence or immediate capitulation.
FAQ
Is the 15-working-day response window a hard legal deadline?
It's a norm from FDA's Regulatory Procedures Manual, not a statute — but missing it without explanation, or providing an incomplete response, both work against a firm during FDA's adequacy review.
Should we hire outside counsel or a consultant immediately?
Many firms do bring in outside regulatory counsel or a subject-matter consultant early, especially for a first Warning Letter, but FDA's own enforcement history shows hiring a consultant alone doesn't guarantee an adequate response if the underlying corrective action still doesn't address the root cause.
Do we need to stop shipping product immediately?
Only if the citation reflects an active risk to product quality or safety that justifies it — there's no blanket FDA rule requiring a full shutdown, and an overly broad pause can create its own problems without addressing the specific cited issue.
What if we disagree with FDA's citation?
The written response is the place to state that disagreement, with supporting data, rather than silence or informal pushback. FDA's process allows for a company to explain why it believes an observation is incorrect or already adequately addressed, as part of the formal response.
Related reading
- What actually makes an FDA warning letter response "adequate" enough to close out?
- How long does a company have to respond to an FDA Warning Letter?
- What is an FDA Warning Letter Close-Out Letter?
Founding rates end when 10 signup →
Sources: FDA Regulatory Procedures Manual, Chapter 4, FDA: Warning Letters, 21 CFR Part 211 (eCFR). Byline: The Argus Regulatory Analysis Team. Published 2026-07-16.